{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:29:23Z","timestamp":1789813763333,"version":"4.0.1"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Octapharma France"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe the characteristics of patients suffering from secondary immunodeficiencies (<jats:styled-content style=\"fixed-case\">SID<\/jats:styled-content>) associated with hematological malignancies (<jats:styled-content style=\"fixed-case\">HM<\/jats:styled-content>), who started immunoglobulin replacement therapy (Ig<jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content>), physicians\u2019 expectations regarding Ig<jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content>, and Ig<jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content> modalities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Non\u2010interventional, prospective French cross\u2010sectional study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The analysis included 231 patients (66\u00a0\u00b1\u00a012\u00a0years old) suffering from multiple myeloma (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>) (N\u00a0=\u00a064), chronic lymphoid leukemia (<jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>) (N\u00a0=\u00a084), aggressive non\u2010Hodgkin B\u2010cell lymphoma (<jats:styled-content style=\"fixed-case\">aNHL<\/jats:styled-content>) (N\u00a0=\u00a032), indolent <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> (N\u00a0=\u00a039), acute leukemia (N\u00a0=\u00a06), and Hodgkin disease (N\u00a0=\u00a06). Of the <jats:styled-content style=\"fixed-case\">HM<\/jats:styled-content>, 47% were currently treated, 42% were relapsing or refractory, 23% of patients had received an autologous hematopoietic stem\u2010cell transplant, and 1% had received an allograft. Serum immunoglobulin trough levels in 195 individuals were less than 5\u00a0g\/L in 68.7% of cases. Most patients had a history of recurrent infections. Immunoglobulin dose was about 400\u00a0mg\/kg\/mo. Half of patients started with subcutaneous infusion. When starting Ig<jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content>, physicians mainly expected to prevent severe and moderate infections. They also anticipated improvement in quality of life and survival which is beyond evidence\u2010based medicine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> is a frequent condition motivating Ig<jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content> besides well\u2010recognized indications. Physicians mainly based the decision of starting Ig<jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content> on hypogammaglobulinemia and recurrence of infections but, irrespective of current recommendations, were also prepared to start Ig<jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content> prophylactically even in the absence of a history of infections.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13078","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T08:50:57Z","timestamp":1523523057000},"page":"48-56","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy\u2010associated secondary immunodeficiency"],"prefix":"10.1111","volume":"101","author":[{"given":"Omar","family":"Benbrahim","sequence":"first","affiliation":[{"name":"H\u00e9matologie H\u00f4pital de La Source CHR Orl\u00e9ans  Orl\u00e9ans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Fran\u00e7ois","family":"Viallard","sequence":"additional","affiliation":[{"name":"M\u00e9decine Interne H\u00f4pital Haut L\u00e9v\u00eaque  Pessac France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[{"name":"H\u00e9matologie GH Piti\u00e9 Salp\u00eatri\u00e8re Assistance Publique\u2010H\u00f4pitaux de Paris  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Royer","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Clinique CHU Amiens \u2010 Sud  Amiens France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Bauduer","sequence":"additional","affiliation":[{"name":"H\u00e9matologie CH C\u00f4te Basque  Bayonne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Decaux","sequence":"additional","affiliation":[{"name":"M\u00e9decine Interne CHU Rennes \u2010 Sud  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Charles","family":"Crave","sequence":"additional","affiliation":[{"name":"Octapharma France  Boulogne\u2010Billancourt France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6800-1777","authenticated-orcid":false,"given":"Yann","family":"Fardini","sequence":"additional","affiliation":[{"name":"Soladis Clinical Studies  Roubaix France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Clerson","sequence":"additional","affiliation":[{"name":"Soladis Clinical Studies  Roubaix France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"L\u00e9vy","sequence":"additional","affiliation":[{"name":"URC\/CRC Groupe Hospitalier Paris Seine Saint Denis APHP, H\u00f4pital Avicenne  Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,17]]},"reference":[{"key":"e_1_2_10_2_1","first-page":"197","article-title":"Prise en charge des d\u00e9ficits secondaires de l'immunit\u00e9 en h\u00e9matologie adulte","volume":"13","author":"Bologna S","year":"2007","journal-title":"M\u00e9decine th\u00e9rapeutique"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.all.0000433132.16436.b5"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2323"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.11.011"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.10.013"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100324"},{"key":"e_1_2_10_8_1","unstructured":"EMA.Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg)EMA\/CHMP\/BPWP\/94038\/2007 Rev. 4. 2012.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/12\/WC500136433.pdf"},{"key":"e_1_2_10_9_1","unstructured":"EMA.Core summary of product characteristics for human normal immunoglobulin for subcutaneous and intramuscular administrationEMA\/CHMP\/BPWP\/410415\/2011 rev 1. 2015.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/03\/WC500184870.pdf"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00626"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2014.09.009"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12900"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2013.769279"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldn034"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-014-9995-5"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06705.x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2086"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24654"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl141"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.101261"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.01.036"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1348-0421.12060"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2016.06.006"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1208085"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir073"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.12.010"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2013.02.021"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810063191403"},{"key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood.V73.2.366.366","article-title":"Crossover study of immunoglobulin replacement therapy in patients with low\u2010grade B\u2010cell tumors","volume":"73","author":"Griffiths H","year":"1989","journal-title":"Blood"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb05002.x"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb01874.x"},{"key":"e_1_2_10_32_1","first-page":"121","article-title":"Prophylaxis against infections with low\u2010dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study","volume":"81","author":"Molica S","year":"1996","journal-title":"Haematologica"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90180-5"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902856824"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.126763"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8450"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444700"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13078","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T02:05:06Z","timestamp":1695434706000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,17]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/ejh.13078"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13078","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,17]]},"assertion":[{"value":"2018-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}